Close

Valeant Pharma (VRX) Announces Brodalumab FDA Advisory Committee Meeting On July 19

June 9, 2016 5:42 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Dermatologic and Ophthalmic Drugs Advisory Committee will review Valeant's New Drug Application (NDA) for brodalumab on July 19, 2016.

On January 25, 2016, Valeant announced that the FDA had accepted for review the Biologics License Application (BLA) submitted by AstraZeneca (LSE/SSE/NYSE: AZN) in partnership with Valeant for brodalumab injection, 210 mg, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate to severe plaque psoriasis. The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016.

"Plaque psoriasis is a chronic disease of the immune system that can impair many aspects of patients' lives," said Joseph C. Papa, chairman and chief executive officer. "We look forward to the opportunity to discuss brodalumab treatment options for adult patients with moderate to severe plaque psoriasis and provide information about this novel antibody we are developing."

As previously announced, the Marketing Authorisation Application (MAA) for brodalumab in psoriasis was accepted by the European Medicines Agency (EMA) in Q42015. In October, 2015, Valeant entered into a collaboration agreement with AstraZeneca under which Valeant has an exclusive license to develop and commercialise brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co., Ltd.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Management Comments

Related Entities

PDUFA, AdCom